<SEC-DOCUMENT>0001193125-17-300312.txt : 20171002
<SEC-HEADER>0001193125-17-300312.hdr.sgml : 20171002
<ACCEPTANCE-DATETIME>20171002080603
ACCESSION NUMBER:		0001193125-17-300312
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170926
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171002
DATE AS OF CHANGE:		20171002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		171113098

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d467810d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D. C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): September&nbsp;26, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PRECIPIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36439</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>91-1789357</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4 Science Park, New Haven, CT 06511 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(203) 787-7888 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name, former address and former fiscal year, if changed since last report date) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment of New Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;26, 2017, Precipio, Inc. (the &#147;Company&#148;) elected each of Douglas Fisher, M.D. and Jeffrey Cossman, M.D. to the Board of Directors of the Company (the &#147;Board&#148;) to fill existing vacancies on the Board, each to serve
until the Company&#146;s 2018 annual meeting of stockholders or his earlier resignation, retirement or removal. The Board also appointed Dr.&nbsp;Fisher to serve as a member of the Audit Committee and Compensation Committee of the Board and
appointed Dr.&nbsp;Cossman to serve as a member of the Compensation Committee and the chair of the Nominating and Corporate Governance Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has affirmatively determined that each of Dr.&nbsp;Fisher and Dr.&nbsp;Cossman is an independent director in accordance with the
standards for independence set forth in the Nasdaq Stock Market Rules and, with respect to Dr.&nbsp;Fisher, the rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;) applicable to audit committee members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March
2009. Dr.&nbsp;Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr.&nbsp;Fisher served as Vice President of New Leaf Venture Partners LLC, a private
equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr.&nbsp;Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006.
Dr.&nbsp;Fisher currently serves on the board of Obalon Therapeutics, Inc., Gynesonics, Inc., and Indi Molecular, Inc. and previously served on the board of QuatRx Pharmaceuticals Company, Cardiac Dimensions, PMV Pharmaceuticals, Inc. and Sera
Prognostics, Inc. Dr.&nbsp;Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Cossman was a founder of, and served as Chief Executive Officer and Chairman of the Board at, United States Diagnostic Standards,
Inc. from 2009 to 2014 and served as a member of the board of directors of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and a member of the board of directors of The Critical Path
Institute and as Medical Director of Gene Logic, Inc.; he was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center and held the Oscar Benwood Hunter Chair of Pathology at Georgetown; and he served as Senior
Investigator in Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr.&nbsp;Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is
board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fisher and Dr.&nbsp;Cossman will be compensated for their service as non-employee directors under the Company&#146;s policy for
non-employee director compensation described in the Company&#146;s Annual Report filed on April&nbsp;13, 2017. In connection with the election of Dr.&nbsp;Fisher and Dr.&nbsp;Cossman and pursuant to this program, the Company granted to each of
Dr.&nbsp;Fisher and Dr.&nbsp;Cossman an option to purchase 7,000 shares of the Company&#146;s common stock under the Company&#146;s 2017 Stock Option and Incentive Plan. The stock options vest monthly over a period of three years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Dr.&nbsp;Fisher nor Dr.&nbsp;Cossman is a party to any transaction with the Company that
would require disclosure under Item&nbsp;404(a) of Regulation S-K, and there are no arrangements or understandings between either Dr.&nbsp;Fisher or Dr.&nbsp;Cossman and any other persons pursuant to which Dr.&nbsp;Fisher or Dr.&nbsp;Cossman was
selected as a director of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Company&#146;s press release regarding the election of Dr.&nbsp;Fisher and
Dr.&nbsp;Cossman is attached hereto as Exhibit 99.1 and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d467810dex991.htm">Press release issued by Precipio, Inc. dated October 2, 2017, furnished hereto. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PRECIPIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ilan Danieli</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ilan Danieli</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;2, 2017</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d467810dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g467810g07f27.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Precipio Elects Jeffrey Cossman, MD, and Douglas Fisher, MD to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW HAVEN, Conn., (October 2, 2017) &#150;</B> Precipio, Inc. (NASDAQ: PRPO), today announced that on September&nbsp;26, 2017, the Company elected each of
Jeffrey Cossman, MD, and Doug Fisher, MD to the Board of Directors of the Company (the &#147;Board&#148;) to fill existing vacancies on the Board. The Board also appointed Dr.&nbsp;Fisher to serve as a member of the Audit Committee and Compensation
Committee of the Board and appointed Dr.&nbsp;Cossman to serve as a member of the Compensation Committee and the chair of the Nominating and Corporate Governance Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are thrilled to appoint both Jeff and Doug to the Board as their expertise and achievements in their respective fields will serve to provide
stewardship and counsel in our efforts to execute on the promise that Precipio represents,&#148; said Ilan Danieli, CEO of Precipio. &#147;Both Jeff and Doug add to the diversity of the backgrounds of our board members, creating a broad basis of
expertise for myself and my management team to rely on. I welcome each of them to the Board and look forward to our fruitful and highly productive relationships,&#148; he added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As a cancer physician, I am honored to be part of Precipio, which promises to improve the lives of those suffering from cancer,&#148; said
Dr.&nbsp;Cossman. &#147;Patients with cancer deserve to have the most accurate diagnosis leading them to the right treatment. Precipio has changed the way this is achieved by giving patients direct, efficient access to world-class diagnostic experts
and laboratories,&#148; he concluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited to join the Precipio team to help bring better care to patients and improve health outcomes.
Misdiagnoses are a major issue for cancer patients, and Precipio&#146;s unique approach will help solve this problem,&#148; said Dr.&nbsp;Fisher. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009.
Dr.&nbsp;Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr.&nbsp;Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and
venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr.&nbsp;Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006. Dr.&nbsp;Fisher
currently serves on the board of Obalon Therapeutics, Inc., Gynesonics, Inc., and Indi Molecular, Inc. and previously served on the board of QuatRx Pharmaceuticals Company, Cardiac Dimensions, PMV Pharmaceuticals, Inc. and Sera Prognostics, Inc.
Dr.&nbsp;Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of Business at the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Cossman was a founder of, and served as Chief Executive Officer and Chairman of the Board at, United States Diagnostic Standards, Inc. from 2009 to
2014 and served as a member of the board of directors of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and a member of the board of directors of The Critical Path Institute and as Medical
Director of Gene Logic, Inc.; he was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center and held the Oscar Benwood Hunter Chair of Pathology at Georgetown; he served as Senior Investigator in
Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr.&nbsp;Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in
pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Precipio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic
institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale
School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Precipio Investor Relations: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Marco </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Core IR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">377 Oak Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garden City, NY 11530 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">516 222 2560 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">johnm@coreir.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.coreir.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g467810g07f27.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g467810g07f27.gif
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MVL8@Q#UDR QBX*#KKKSVZNNOOQ:B$0,LC)!&(88DJ^RRR5J1+!PQ:&F0$CB
M(6U!#+P:Z[:CML%(K0Z-, 8;K%Y$[ AS&!)&&#ND,<(%B%54BHO]!2JH;+(!
M!<PY"E70S 0BW(! (D,P,% DZ["#0#N/* $ "^Y@VB.5(YJ  FH;&?)##CE
M\004'(<L\L@A_V#R(DL8LEU#:)#L\LL<FWQ%)6/,83!#<T#A \P\]^SR&A;Q
M, <.1.!Q!10@^RQR&0<9XH,/:A@4R0P<?ZRTR$^8_,/,-=_,T!AQY'!'1=FJ
M48;127,,Q14HAW%'N1$)(]Y/]HXIV5.U\"(3_D(76.()N G!#< V4Z# X)P5
MH_ I1F#(\?3CD$<N>>0YZ.!#)6%XG9 DCD_NN><ZY+ S&6DP%,;5J+_L0QU
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M00NA<TX0!_,8.:$ 7! A"GC@ XNPB["F>=16//WX.?5XC\HSB .QC,U($F$
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M,<>B$0)8,-=]DMJJS1'0.\.E"-# =%"9P@$U( 530 55(+*D_1DA< 0:O-K
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M $ "$5 ""E+B<X("!""6 C  *:"P5E[F+GX!&) !&K !6>8!'^ !3PX<?3$
M(E !^&WF>*[?#-  . [P ! 0 1)@>YNQJ@90 1; X7F>Z.G-MXQ2  9P  B0
:  J QHI>Z99^Z9B>Z9J^Z9S>Z9Z^$@$! #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
